Suppr超能文献

脑性瘫痪患者外显子组测序的分子诊断率。

Molecular Diagnostic Yield of Exome Sequencing in Patients With Cerebral Palsy.

机构信息

Autism & Developmental Medicine Institute, Geisinger, Danville, Pennsylvania.

Genomic Medicine Institute, Geisinger, Danville, Pennsylvania.

出版信息

JAMA. 2021 Feb 2;325(5):467-475. doi: 10.1001/jama.2020.26148.

Abstract

IMPORTANCE

Cerebral palsy is a common neurodevelopmental disorder affecting movement and posture that often co-occurs with other neurodevelopmental disorders. Individual cases of cerebral palsy are often attributed to birth asphyxia; however, recent studies indicate that asphyxia accounts for less than 10% of cerebral palsy cases.

OBJECTIVE

To determine the molecular diagnostic yield of exome sequencing (prevalence of pathogenic and likely pathogenic variants) in individuals with cerebral palsy.

DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study of patients with cerebral palsy that included a clinical laboratory referral cohort with data accrued between 2012 and 2018 and a health care-based cohort with data accrued between 2007 and 2017.

EXPOSURES

Exome sequencing with copy number variant detection.

MAIN OUTCOMES AND MEASURES

The primary outcome was the molecular diagnostic yield of exome sequencing.

RESULTS

Among 1345 patients from the clinical laboratory referral cohort, the median age was 8.8 years (interquartile range, 4.4-14.7 years; range, 0.1-66 years) and 601 (45%) were female. Among 181 patients in the health care-based cohort, the median age was 41.9 years (interquartile range, 28.0-59.6 years; range, 4.8-89 years) and 96 (53%) were female. The molecular diagnostic yield of exome sequencing was 32.7% (95% CI, 30.2%-35.2%) in the clinical laboratory referral cohort and 10.5% (95% CI, 6.0%-15.0%) in the health care-based cohort. The molecular diagnostic yield ranged from 11.2% (95% CI, 6.4%-16.2%) for patients without intellectual disability, epilepsy, or autism spectrum disorder to 32.9% (95% CI, 25.7%-40.1%) for patients with all 3 comorbidities. Pathogenic and likely pathogenic variants were identified in 229 genes (29.5% of 1526 patients); 86 genes were mutated in 2 or more patients (20.1% of 1526 patients) and 10 genes with mutations were independently identified in both cohorts (2.9% of 1526 patients).

CONCLUSIONS AND RELEVANCE

Among 2 cohorts of patients with cerebral palsy who underwent exome sequencing, the prevalence of pathogenic and likely pathogenic variants was 32.7% in a cohort that predominantly consisted of pediatric patients and 10.5% in a cohort that predominantly consisted of adult patients. Further research is needed to understand the clinical implications of these findings.

摘要

重要性

脑瘫是一种常见的神经发育障碍,影响运动和姿势,常与其他神经发育障碍同时发生。脑瘫的个别病例通常归因于出生窒息;然而,最近的研究表明,窒息仅占脑瘫病例的不到 10%。

目的

确定外显子组测序(致病性和可能致病性变异的患病率)在脑瘫患者中的分子诊断率。

设计、设置和参与者:这是一项回顾性队列研究,纳入了脑瘫患者,包括一个临床实验室转诊队列和一个健康护理为基础的队列。临床实验室转诊队列的数据在 2012 年至 2018 年期间收集,健康护理为基础的队列的数据在 2007 年至 2017 年期间收集。

暴露

外显子组测序与拷贝数变异检测。

主要结局和措施

主要结局是外显子组测序的分子诊断率。

结果

在临床实验室转诊队列的 1345 名患者中,中位年龄为 8.8 岁(四分位距,4.4-14.7 岁;范围,0.1-66 岁),601 名(45%)为女性。在健康护理为基础的队列的 181 名患者中,中位年龄为 41.9 岁(四分位距,28.0-59.6 岁;范围,4.8-89 岁),96 名(53%)为女性。外显子组测序的分子诊断率在临床实验室转诊队列中为 32.7%(95%置信区间,30.2%-35.2%),在健康护理为基础的队列中为 10.5%(95%置信区间,6.0%-15.0%)。在无智力障碍、癫痫或自闭症谱系障碍的患者中,分子诊断率为 11.2%(95%置信区间,6.4%-16.2%),而在同时患有所有 3 种合并症的患者中,分子诊断率为 32.9%(95%置信区间,25.7%-40.1%)。在 229 个基因中发现了致病性和可能致病性变异(1526 名患者中有 29.5%);有 86 个基因在 2 个或更多患者中发生突变(1526 名患者中有 20.1%),在这两个队列中均独立发现了 10 个具有突变的基因(1526 名患者中有 2.9%)。

结论和相关性

在接受外显子组测序的 2 个脑瘫患者队列中,致病性和可能致病性变异的患病率在主要由儿科患者组成的队列中为 32.7%,在主要由成年患者组成的队列中为 10.5%。需要进一步研究以了解这些发现的临床意义。

相似文献

5
Genetic testing in individuals with cerebral palsy.脑性瘫痪患者的基因检测。
Dev Med Child Neurol. 2021 Dec;63(12):1448-1455. doi: 10.1111/dmcn.14948. Epub 2021 Jun 10.

引用本文的文献

1
Genetic Testing of Neurodevelopmental Disorders in Israel.以色列神经发育障碍的基因检测
JAMA Netw Open. 2025 Aug 1;8(8):e2527464. doi: 10.1001/jamanetworkopen.2025.27464.
4
Insights into the genetic landscape of cerebral palsy.对脑瘫遗传图谱的见解。
Clin Transl Med. 2025 Jul;15(7):e70412. doi: 10.1002/ctm2.70412.
7

本文引用的文献

1
Mutations disrupting neuritogenesis genes confer risk for cerebral palsy.突变破坏神经发生基因会增加脑瘫的风险。
Nat Genet. 2020 Oct;52(10):1046-1056. doi: 10.1038/s41588-020-0695-1. Epub 2020 Sep 28.
4
GNAO1 mutation presenting as dyskinetic cerebral palsy.表现为运动障碍型脑性瘫痪的GNAO1基因突变
Neurol Sci. 2019 Oct;40(10):2213-2216. doi: 10.1007/s10072-019-03964-7. Epub 2019 Jun 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验